What's happening with 23andMe? Mass layoffs and restructuring are the latest blow for the embattled DNA testing company
DNA-testing company 23andMe (Nasdaq: ME), once an industry leader that attracted millions of customers, including rapper Snoop Dogg and investor Warren Buffett, has announced significant cuts to its operations, with plans to lay off 200 employees, or roughly 40% of its workforce. The company also said it will discontinue development of its therapeutic programs.
Here's Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader Market
Ginkgo Bioworks Holdings, Inc. (DNA) closed at $7.63 in the latest trading session, marking a -1.55% move from the prior day.
Applied DNA Announces Pricing of $6.5 Million Registered Direct Offering and Concurrent Private Placement
STONY BROOK, NY / ACCESSWIRE / October 30, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the pricing of a registered direct offering and concurrent private placement with gross proceeds to the Company expected to be approximately $6.5 million before deducting placement agent fees and other estimated expenses payable by the Company. The offering is comprised of 20,312,500 shares (the "Shares") of the Company's common stock (or pre-funded warrants in lieu thereof) at a purchase price of $0.32 per share of common stock (or pre-funded warrants in lieu thereof, which shall have the same purchase price, less the exercise price of $0.0001) in a registered direct offering priced at-the-market under Nasdaq rules.
Applied DNA to Participate in the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16
STONY BROOK, NY / ACCESSWIRE / October 15, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA"), a leader in PCR-based DNA technologies, today announced that Dr. James A. Hayward, president and chief executive officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit.
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Slides as Market Rises: Facts to Know Before You Trade
Ginkgo Bioworks Holdings, Inc. (DNA) closed the most recent trading day at $7.70, moving -0.77% from the previous trading session.
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement
STONY BROOK, NY / ACCESSWIRE / September 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that on September 17, 2024, it received a notification letter (the "Notification Letter") from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq"), informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). As previously reported, the Company was notified on July 12, 2024, that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Minimum Bid Price Requirement.
Why Ginkgo Bioworks Holdings Stock Raced 9% Higher Today
The biotech rolled out two new healthtech innovations. One is a large language model (LLM) developed with its partner Alphabet.
Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 3rd Annual mRNA Process Development & Manufacturing Summit
- Co-Hosts Seminar with mRNA CDMO Kudo Bio to Demonstrate Linea IVT Capability for Rapid mRNA Manufacturing - STONY BROOK, NY / ACCESSWIRE / September 17, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced its participation at upcoming mRNA events in Boston this week: 3rd Annual mRNA Process Development & Manufacturing Summit - members of Applied DNA's Biotherapeutics Sales and Business Development teams (collectively 'LineaRx,' a majority-owned Applied DNA company) will attend the 3rd Annual mRNA Process Development & Manufacturing Summit taking place September 17-19, 2024. LineaRx will present its Linea™ IVT platform - a combination of an enzymatically produced DNA template (Linea™ DNA IVT template) coupled with a next-generation RNA polymerase (Linea™ RNAP) - as a solution to enable mRNA producers to manufacture better mRNA faster via simplified workflows and reduced double-stranded RNA (dsRNA) contamination.
Applied DNA Receives Linea DNA Follow-on Order from Global Manufacturer of IVDs for Cancer Diagnostic Application
- Recurring and Accelerated Receipt of Order Reflects Customer Commitment to Linea DNA - STONY BROOK, NY / ACCESSWIRE / September 17, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced it has received a follow-on order valued at more than $500,000 for a quantity of Linea™ DNA from a global manufacturer of in vitro diagnostics (IVDs). The follow-on order was placed under a long-standing supply agreement for the bulk manufacture of Linea DNA (non-therapeutic) used in the manufacture of a cancer diagnostic test.
Applied DNA Launches Mpox Clade I and Clade II Testing Service
STONY BROOK, NY / ACCESSWIRE / September 11, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), has launched an expansion of its clinical testing services for the detection of Mpox (formerly monkeypox) to include testing for both mpox Clade I and Clade II. The launch of the expanded mpox testing service comes after ADCL's interaction with relevant regulatory bodies, including the New York State Department of Health (NYSDOH) and the U.S. Food and Drug Administration (FDA).
Down a Monstrous 90% This Year, Is There Any Hope Left for Ginkgo Bioworks Investors?
Ginkgo Bioworks hopes to revolutionize many industries with bioengineered products. Its business, however, remains deeply unprofitable.
Applied DNA Selected by LRQA for Isotopic Testing Pilot Project in Pakistan
- Pilot Project To Demonstrate Effectiveness of CertainT® for Cotton Textile Traceability - STONY BROOK, NY / ACCESSWIRE / September 4, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced the receipt of a subcontract award from LRQA following a competitive tender for a pilot isotopic testing program. Under the terms of the subcontract, Applied DNA, together with its traceability partner, Isotech (a Stratum Reservoir company), will employ CertainT® to conduct isotopic testing and analysis to support cotton traceability in Pakistan.
